Trial Profile
B-Cell Targeted Desensitization With Carfilzomib for Preformed Anti-HLA Antibodies in Patients Awaiting Kidney Transplantation
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 06 Jun 2022
Price :
$35
*
At a glance
- Drugs Carfilzomib (Primary) ; Rituximab
- Indications Renal transplant rejection
- Focus Adverse reactions
- 29 Jun 2020 Planned End Date changed from 1 Sep 2019 to 1 Sep 2021.
- 29 Jun 2020 Planned primary completion date changed from 1 Jun 2019 to 1 Jun 2021.
- 24 Sep 2019 Results assessing safety, toxicity and preliminary efficacy of carfilzomib in highly HLA- sensitized kidney transplant candidates published in the American Journal of Transplantation